The Current Ratio as of September 2024 (TTM) for Werewolf Therapeutics, Inc. (HOWL) is 12.13

According to Werewolf Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.13. This represents a change of -39.44% compared to the average of 20.03 of the last 4 quarters.

Werewolf Therapeutics, Inc. (HOWL) Historical Current Ratio (quarterly & annually)

How has HOWL Current Ratio performed in the past?

The mean historical Current Ratio of Werewolf Therapeutics, Inc. over the last ten years is 10.59. The current 12.13 Current Ratio has changed 11.35% with respect to the historical average. Over the past ten years (40 quarters), HOWL's Current Ratio was at its highest in in the September 2023 quarter at 54.15. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Werewolf Therapeutics, Inc. (HOWL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Werewolf Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Werewolf Therapeutics, Inc. (HOWL) Average Current Ratio

How has HOWL Current Ratio performed in the past?

The current Current Ratio of Werewolf Therapeutics, Inc. (HOWL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Werewolf Therapeutics, Inc. (HOWL) Current Ratio vs. Peers

How is HOWL’s Current Ratio compared to its peers?

Werewolf Therapeutics, Inc.’s Current Ratio is greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), less than Edgewise Therapeutics, Inc. (30.24), greater than Decibel Therapeutics, Inc. (3.03), less than Celcuity Inc. (14.95), greater than C4 Therapeutics, Inc. (5.09), less than Talaris Therapeutics, Inc. (18.64), less than Adicet Bio, Inc. (12.75), less than Cullinan Oncology, Inc. (28.87), greater than Vor Biopharma Inc. (6.54), less than Third Harmonic Bio, Inc. (41.13), greater than Passage Bio, Inc. (7.67), less than Acrivon Therapeutics, Inc. Common Stock (16.16), less than Eliem Therapeutics, Inc. (60.41), less than Molecular Partners AG (14.58), less than MediciNova, Inc. (18.24), greater than Anebulo Pharmaceuticals, Inc. (5.32), greater than Champions Oncology, Inc. (0.69), less than Cyteir Therapeutics, Inc. (21.89),

Build a custom stock screener for Werewolf Therapeutics, Inc. (HOWL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Werewolf Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Werewolf Therapeutics, Inc. (HOWL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Werewolf Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.